ScreenerHero

IMVT Immunovant, Inc.

NAS · US · Healthcare · Biotechnology · immunovant.com
32.04USD-0.22%Mkt Cap: 6.62B $P/E: —

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap6.62B USD
Enterprise Value5.83B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-505.61M USD
Revenue/Share—
Last Price32.04 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees315
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.68
PEG—
EV/EBITDA-10.32
EV/Revenue—
P/S—
P/B9.01
EPS (TTM)-2.73
EPS (Forward)-2.75
52W Range
15.2256% of range45.35
52W High45.35 USD
52W Low15.22 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-59.30%
ROA-52.83%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-407.31M USD
CapEx (TTM)8.00K USD
FCF Margin—
FCF Yield-3.61%
Net Debt-797.80M USD
Net Debt/EBITDA1.41
Balance Sheet
Debt/Equity0.00
Current Ratio7.27
Quick Ratio6.82
Book Value/Sh3.56 USD
Cash/Share3.86 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)48.88 USD
Upside (mean)+52.5%
Target Range30.00 USD – 66.00 USD
30.00+52.5% to mean66.00
# Analysts16
Ownership
Shares Out.206.55M
Float91.79M
Insiders56.02%
Institutions53.95%
Short Interest
Short Ratio14.6d
Short % Float18.57%
Short % Out.8.35%
Shares Short17.25M
Short (prev mo.)16.98M
Technical
SMA 5039.04 (-17.9%)
SMA 20031.77 (+0.8%)
Beta0.84
S&P 52W Chg16.45%
Avg Vol (30d)1.38M
Avg Vol (10d)1.75M
Technical Indicators
RSI (14)23.9
MACD-1.8565
MACD Signal-1.6298
MACD Hist.-0.2267
BB Upper40.05 USD
BB Middle35.34 USD
BB Lower30.62 USD
BB Width26.68%
ATR (14)1.425 USD
Vol Ratio (20d)0.76x